Botanical-Drug Interactions: A Scientific Perspective

Abstract

There is a continued predisposition of concurrent use of drugs and botanical products. A general lack of knowledge of the interaction potential together with an under-reporting of botanical use poses a challenge for the health care providers and a safety concern for patients. Botanical-drug interactions increase the patient risk, especially with regard to drugs with a narrow therapeutic index (e.g., warfarin, cyclosporine, and digoxin). Examples of case reports and clinical studies evaluating botanical-drug interactions of commonly used botanicals in the US are presented. The potential pharmacokinetic and pharmacodynamic bases of such interactions are discussed, as well as the challenges associated with the interpretation of the available data and prediction of botanical-drug interactions. Recent FDA experiences with botanical products and interactions including labeling implications as a risk management strategy are highlighted.

Key words

drug-interactions - botanical products - regulatory science - clinical pharmacology

• References

• 1 American Botanical Council. Herbal supplements sale rise in all channels in 2009. Herbalgram 2010; 86: 62-65
• 2 Bardia A, Nisly NL, Zimmerman MB, Gryzlak BM, Wallace RB. Use of herbs among adults based on evidence-based indications: findings from the National Health Interview Survey. Mayo Clin Proc 2007; 82: 561-566
• 3 Bent S. Herbal medicine in the United States: review of efficacy, safety, and regulation: grand rounds at University of California, San Francisco Medical Center. J Gen Intern Med 2008; 23: 854-859
• 4 Hensrud DD, Engle DD, Scheitel SM. Underreporting the use of dietary supplements and nonprescription medications among patients undergoing a periodic health examination. Mayo Clin Proc 1999; 74: 443-447
• 5 Ernst E. Herb-drug interactions: potentially important but woefully under-researched. Eur J Clin Pharmacol 2000; 56: 523-524
• 6 Dodge T, Litt D, Kaufman A. Influence of the dietary supplement health and education act on consumer beliefs about the safety and effectiveness of dietary supplements. J Health Commun 2011; 16: 230-244
• 7 Fugh-Berman A. Herb-drug interactions. Lancet 2000; 355: 134-138
• 8 Ruschitzka F, Meier PJ, Turina M, Luscher TF, Noll G. Acute heart transplant rejection due to Saint Johnʼs wort. Lancet 2000; 355: 548-549
• 9 Mathijssen RH, Verweij J, de Bruijn P, Loos WJ, Sparreboom A. Effects of St. Johnʼs wort on irinotecan metabolism. J Natl Cancer Inst 2002; 94: 1247-1249
• 10 Zhou SF, Zhou ZW, Li CG, Chen X, Yu X, Xue CC, Herington A. Identification of drugs that interact with herbs in drug development. Drug Discov Today 2007; 12: 664-673
• 11 Wienkers LC, Heath TG. Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov 2005; 4: 825-833
• 12 Lam Y, Huang SM, Hall SD. Drug interactions with botanical products. In: Lam Y, Huang S, Hall S, editors Herbal supplements-drug interactions – Scientific and regulatory perspectives. Drugs and the pharmaceutical sciences. New York: Taylor & Francis; 2006: 25-47
• 13 Guillemette C. Pharmacogenomics of human UDP-glucuronosyltransferase enzymes. Pharmacogenomics J 2003; 3: 136-158
• 14 Obach RS, Walsky RL, Venkatakrishnan K. Mechanism-based inactivation of human cytochrome p 450 enzymes and the prediction of drug-drug interactions. Drug Metab Dispos 2007; 35: 246-255
• 15 Zhou S, Koh HL, Gao Y, Gong ZY, Lee EJ. Herbal bioactivation: the good, the bad and the ugly. Life Sci 2004; 74: 935-968
• 16 Tarirai C, Viljoen AM, Hamman JH. Herb-drug pharmacokinetic interactions reviewed. Expert Opin Drug Metab Toxicol 2010; 6: 1515-1538
• 17 Sridar C, Goosen TC, Kent UM, Williams JA, Hollenberg PF. Silybin inactivates cytochromes P450 3A4 and 2C9 and inhibits major hepatic glucuronosyltransferases. Drug Metab Dispos 2004; 32: 587-594
• 18 Tassaneeyakul W, Guo LQ, Fukuda K, Ohta T, Yamazoe Y. Inhibition selectivity of grapefruit juice components on human cytochromes P450. Arch Biochem Biophys 2000; 378: 356-363
• 19 Guo LQ, Yamazoe Y. Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines. Acta Pharmacol Sin 2004; 25: 129-136
• 20 Schmiedlin-Ren P, Edwards DJ, Fitzsimmons ME, He K, Lown KS, Woster PM, Rahman A, Thummel KE, Fisher JM, Hollenberg PF, Watkins PB. Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents. Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins. Drug Metab Dispos 1997; 25: 1228-1233
• 21 Lown KS, Bailey DG, Fontana RJ, Janardan SK, Adair CH, Fortlage LA, Brown MB, Guo W, Watkins PB. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest 1997; 99: 2545-2553
• 22 Hanley MJ, Cancalon P, Widmer WW, Greenblatt DJ. The effect of grapefruit juice on drug disposition. Expert Opin Drug Metab Toxicol 2011; 7: 267-286
• 23 Xin HW, Wu XC, Li Q, Yu AR, Zhong MY, Liu YY. The effects of berberine on the pharmacokinetics of cyclosporin A in healthy volunteers. Methods Find Exp Clin Pharmacol 2006; 28: 25-29
• 24 Wu X, Li Q, Xin H, Yu A, Zhong M. Effects of berberine on the blood concentration of cyclosporin A in renal transplanted recipients: clinical and pharmacokinetic study. Eur J Clin Pharmacol 2005; 61: 567-572
• 25 Foster BC, Vandenhoek S, Hana J, Krantis A, Akhtar MH, Bryan M, Budzinski JW, Ramputh A, Arnason JT. In vitro inhibition of human cytochrome P450-mediated metabolism of marker substrates by natural products. Phytomedicine 2003; 10: 334-342
• 26 Raner GM, Cornelious S, Moulick K, Wang Y, Mortenson A, Cech NB. Effects of herbal products and their constituents on human cytochrome P450(2E1) activity. Food Chem Toxicol 2007; 45: 2359-2365
• 27 Etheridge AS, Black SR, Patel PR, So J, Mathews JM. An in vitro evaluation of cytochrome P450 inhibition and P-glycoprotein interaction with goldenseal, Ginkgo biloba, grape seed, milk thistle, and ginseng extracts and their constituents. Planta Med 2007; 73: 731-741
• 28 Budzinski JW, Trudeau VL, Drouin CE, Panahi M, Arnason JT, Foster BC. Modulation of human cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp) in Caco-2 cell monolayers by selected commercial-source milk thistle and goldenseal products. Can J Physiol Pharmacol 2007; 85: 966-978
• 29 Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Khan IA, Shah A. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin Pharmacol Ther 2005; 77: 415-426
• 30 Gurley BJ, Swain A, Hubbard MA, Williams DK, Barone G, Hartsfield F, Tong Y, Carrier DJ, Cheboyina S, Battu SK. Clinical assessment of CYP2D6-mediated herb-drug interactions in humans: effects of milk thistle, black cohosh, goldenseal, kava kava, St. Johnʼs wort, and Echinacea . Mol Nutr Food Res 2008; 52: 755-763
• 31 Gurley BJ, Swain A, Hubbard MA, Hartsfield F, Thaden J, Williams DK, Gentry WB, Tong Y. Supplementation with goldenseal (Hydrastis canadensis), but not kava kava (Piper methysticum), inhibits human CYP3A activity in vivo . Clin Pharmacol Ther 2008; 83: 61-69
• 32 Hewitt NJ, Lecluyse EL, Ferguson SS. Induction of hepatic cytochrome P450 enzymes: methods, mechanisms, recommendations, and in vitro-in vivo correlations. Xenobiotica 2007; 37: 1196-1224
• 33 di Masi A, De Marinis E, Ascenzi P, Marino M. Nuclear receptors CAR and PXR: Molecular, functional, and biomedical aspects. Mol Aspects Med 2009; 30: 297-343
• 34 Komoroski BJ, Zhang S, Cai H, Hutzler JM, Frye R, Tracy TS, Strom SC, Lehmann T, Ang CY, Cui YY, Venkataramanan R. Induction and inhibition of cytochromes P450 by the St. Johnʼs wort constituent hyperforin in human hepatocyte cultures. Drug Metab Dispos 2004; 32: 512-518
• 35 Moore LB, Goodwin B, Jones SA, Wisely GB, Serabjit-Singh CJ, Willson TM, Collins JL, Kliewer SA. St. Johnʼs wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci USA 2000; 97: 7500-7502
• 36 Kober M, Pohl K, Efferth T. Molecular mechanisms underlying St. Johnʼs wort drug interactions. Curr Drug Metab 2008; 9: 1027-1037
• 37 Wentworth JM, Agostini M, Love J, Schwabe JW, Chatterjee VK. St Johnʼs wort, a herbal antidepressant, activates the steroid X receptor. J Endocrinol 2000; 166: R11-R16
• 38 de Maat MM, Hoetelmans RM, Math t RA, van Gorp EC, Meenhorst PL, Mulder JW, Beijnen JH. Drug interaction between St Johnʼs wort and nevirapine. AIDS 2001; 15: 420-421
• 39 Portoles A, Terleira A, Calvo A, Martinez I, Resplandy G. Effects of Hypericum perforatum on ivabradine pharmacokinetics in healthy volunteers: an open-label, pharmacokinetic interaction clinical trial. J Clin Pharmacol 2006; 46: 1188-1194
• 40 Kawaguchi A, Ohmori M, Tsuruoka S, Nishiki K, Harada K, Miyamori I, Yano R, Nakamura T, Masada M, Fujimura A. Drug interaction between St Johnʼs Wort and quazepam. Br J Clin Pharmacol 2004; 58: 403-410
• 41 Tannergren C, Engman H, Knutson L, Hedeland M, Bondesson U, Lennernas H. St Johnʼs wort decreases the bioavailability of R- and S-verapamil through induction of the first-pass metabolism. Clin Pharmacol Ther 2004; 75: 298-309
• 42 Jiang X, Williams KM, Liauw WS, Ammit AJ, Roufogalis BD, Duke CC, Day RO, McLachlan AJ. Effect of St Johnʼs wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol 2004; 57: 592-599
• 43 Hellum BH, Hu Z, Nilsen OG. Trade herbal products and induction of CYP2C19 and CYP2E1 in cultured human hepatocytes. Basic Clin Pharmacol Toxicol 2009; 105: 58-63
• 44 Karyekar CS, Eddington ND, Dowling TC. Effect of St. Johnʼs Wort extract on intestinal expression of cytochrome P4501A2: studies in LS180 cells. J Postgrad Med 2002; 48: 97-100
• 45 Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Cui Y, Ang CY. Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly: St Johnʼs wort, garlic oil, Panax ginseng and Ginkgo biloba . Drugs Aging 2005; 22: 525-539
• 46 Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Cui Y, Ang CY. Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. Clin Pharmacol Ther 2002; 72: 276-287
• 47 Wang LS, Zhu B, Abd El-Aty AM, Zhou G, Li Z, Wu J, Chen GL, Liu J, Tang ZR, An W, Li Q, Wang D, Zhou HH. The influence of St Johnʼs Wort on CYP2C19 activity with respect to genotype. J Clin Pharmacol 2004; 44: 577-581
• 48 Wang LS, Zhou G, Zhu B, Wu J, Wang JG, Abd El-Aty AM, Li T, Liu J, Yang TL, Wang D, Zhong XY, Zhou HH. St Johnʼs wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole. Clin Pharmacol Ther 2004; 75: 191-197
• 49 Xu H, Williams KM, Liauw WS, Murray M, Day RO, McLachlan AJ. Effects of St Johnʼs wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazide. Br J Pharmacol 2008; 153: 1579-1586
• 50 Wang Z, Gorski JC, Hamman MA, Huang SM, Lesko LJ, Hall SD. The effects of St Johnʼs wort (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther 2001; 70: 317-326
• 51 Arold G, Donath F, Maurer A, Diefenbach K, Bauer S, Henneicke-von Zepelin HH, Friede M, Roots I. No relevant interaction with alprazolam, caffeine, tolbutamide, and digoxin by treatment with a low-hyperforin St Johnʼs wort extract. Planta Med 2005; 71: 331-337
• 52 Wenk M, Todesco L, Krahenbuhl S. Effect of St Johnʼs wort on the activities of CYP1A2, CYP3A4, CYP2D6, N-acetyltransferase 2, and xanthine oxidase in healthy males and females. Br J Clin Pharmacol 2004; 57: 495-499
• 53 Nebel A, Schneider BJ, Baker RK, Kroll DJ. Potential metabolic interaction between St. Johnʼs wort and theophylline. Ann Pharmacother 1999; 33: 502
• 54 de los Reyes GC, Koda RT. Determining hyperforin and hypericin content in eight brands of St. Johnʼs wort. Am J Health Syst Pharm 2002; 59: 545-547
• 55 Krochmal R, Hardy M, Bowerman S, Lu QY, Wang HJ, Elashoff R, Heber D. Phytochemical assays of commercial botanical dietary supplements. Evid Based Complement Alternat Med 2004; 1: 305-313
• 56 Obach RS. Inhibition of human cytochrome P450 enzymes by constituents of St. Johnʼs Wort, an herbal preparation used in the treatment of depression. J Pharmacol Exp Ther 2000; 294: 88-95
• 57 Hellum BH, Nilsen OG. The in vitro inhibitory potential of trade herbal products on human CYP2D6-mediated metabolism and the influence of ethanol. Basic Clin Pharmacol Toxicol 2007; 101: 350-358
• 58 Rengelshausen J, Banfield M, Riedel KD, Burhenne J, Weiss J, Thomsen T, Walter-Sack I, Haefeli WE, Mikus G. Opposite effects of short-term and long-term St Johnʼs wort intake on voriconazole pharmacokinetics. Clin Pharmacol Ther 2005; 78: 25-33
• 59 Mohutsky MA, Anderson GD, Miller JW, Elmer GW. Ginkgo biloba: evaluation of CYP2C9 drug interactions in vitro and in vivo . Am J Ther 2006; 13: 24-31
• 60 Jiang X, Williams KM, Liauw WS, Ammit AJ, Roufogalis BD, Duke CC, Day RO, McLachlan AJ. Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol 2005; 59: 425-432
• 61 Kim BH, Kim KP, Lim KS, Kim JR, Yoon SH, Cho JY, Lee YO, Lee KH, Jang IJ, Shin SG, Yu KS. Influence of Ginkgo biloba extract on the pharmacodynamic effects and pharmacokinetic properties of ticlopidine: an open-label, randomized, two-period, two-treatment, two-sequence, single-dose crossover study in healthy Korean male volunteers. Clin Ther 2010; 32: 380-390
• 62 Uchida S, Yamada H, Li XD, Maruyama S, Ohmori Y, Oki T, Watanabe H, Umegaki K, Ohashi K, Yamada S. Effects of Ginkgo biloba extract on pharmacokinetics and pharmacodynamics of tolbutamide and midazolam in healthy volunteers. J Clin Pharmacol 2006; 46: 1290-1298
• 63 Liu XP, Goldring CE, Wang HY, Copple IM, Kitteringham NR, Park BK. Extract of Ginkgo biloba induces glutathione-S-transferase subunit-P1 in vitro . Phytomedicine 2009; 16: 451-455
• 64 Sugiyama T, Kubota Y, Shinozuka K, Yamada S, Yamada K, Umegaki K. Induction and recovery of hepatic drug metabolizing enzymes in rats treated with Ginkgo biloba extract. Food Chem Toxicol 2004; 42: 953-957
• 65 Mohamed MF, Frye RF. Inhibition of intestinal and hepatic glucuronidation of mycophenolic acid by Ginkgo biloba extract and flavonoids. Drug Metab Dispos 2010; 38: 270-275
• 66 van Erp NP, Baker SD, Zhao M, Rudek MA, Guchelaar HJ, Nortier JW, Sparreboom A, Gelderblom H. Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecan. Clin Cancer Res 2005; 11: 7800-7806
• 67 Marchetti S, Mazzanti R, Beijnen JH, Schellens JH. Concise review: Clinical relevance of drug drug and herb drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). Oncologist 2007; 12: 927-941
• 68 Matic M, Mahns A, Tsoli M, Corradin A, Polly P, Robertson GR. Pregnane X receptor: promiscuous regulator of detoxification pathways. Int J Biochem Cell Biol 2007; 39: 478-483
• 69 Dasgupta A. Herbal supplements and therapeutic drug monitoring: focus on digoxin immunoassays and interactions with St. Johnʼs wort. Ther Drug Monit 2008; 30: 212-217
• 70 Mueller SC, Uehleke B, Woehling H, Petzsch M, Majcher-Peszynska J, Hehl EM, Sievers H, Frank B, Riethling AK, Drewelow B. Effect of St Johnʼs wort dose and preparations on the pharmacokinetics of digoxin. Clin Pharmacol Ther 2004; 75: 546-557
• 71 Schwarz UI, Hanso H, Oertel R, Miehlke S, Kuhlisch E, Glaeser H, Hitzl M, Dresser GK, Kim RB, Kirch W. Induction of intestinal P-glycoprotein by St Johnʼs wort reduces the oral bioavailability of talinolol. Clin Pharmacol Ther 2007; 81: 669-678
• 72 Wang Z, Hamman MA, Huang SM, Lesko LJ, Hall SD. Effect of St Johnʼs wort on the pharmacokinetics of fexofenadine. Clin Pharmacol Ther 2002; 71: 414-420
• 73 Tian R, Koyabu N, Morimoto S, Shoyama Y, Ohtani H, Sawada Y. Functional induction and de-induction of P-glycoprotein by St. Johnʼs wort and its ingredients in a human colon adenocarcinoma cell line. Drug Metab Dispos 2005; 33: 547-554
• 74 Gutmann H, Poller B, Buter KB, Pfrunder A, Schaffner W, Drewe J. Hypericum perforatum: which constituents may induce intestinal MDR1 and CYP3A4 mRNA expression?. Planta Med 2006; 72: 685-690
• 75 Durr D, Stieger B, Kullak-Ublick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K. St Johnʼs Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 2000; 68: 598-604
• 76 Fan L, Mao XQ, Tao GY, Wang G, Jiang F, Chen Y, Li Q, Zhang W, Lei HP, Hu DL, Huang YF, Wang D, Zhou HH. Effect of Schisandra chinensis extract and Ginkgo biloba extract on the pharmacokinetics of talinolol in healthy volunteers. Xenobiotica 2009; 39: 249-254
• 77 Fan L, Tao GY, Wang G, Chen Y, Zhang W, He YJ, Li Q, Lei HP, Jiang F, Hu DL, Huang YF, Zhou HH. Effects of Ginkgo biloba extract ingestion on the pharmacokinetics of talinolol in healthy Chinese volunteers. Ann Pharmacother 2009; 43: 944-949
• 78 Mauro VF, Mauro LS, Kleshinski JF, Khuder SA, Wang Y, Erhardt PW. Impact of Ginkgo biloba on the pharmacokinetics of digoxin. Am J Ther 2003; 10: 247-251
• 79 Robertson SM, Davey RT, Voell J, Formentini E, Alfaro RM, Penzak SR. Effect of Ginkgo biloba extract on lopinavir, midazolam and fexofenadine pharmacokinetics in healthy subjects. Curr Med Res Opin 2008; 24: 591-599
• 80 Hellum BH, Nilsen OG. In vitro inhibition of CYP3A4 metabolism and P-glycoprotein-mediated transport by trade herbal products. Basic Clin Pharmacol Toxicol 2008; 102: 466-475
• 81 Wang Y, Cao J, Zeng S. Involvement of P-glycoprotein in regulating cellular levels of Ginkgo flavonols: quercetin, kaempferol, and isorhamnetin. J Pharm Pharmacol 2005; 57: 751-758
• 82 Fuchikami H, Satoh H, Tsujimoto M, Ohdo S, Ohtani H, Sawada Y. Effects of herbal extracts on the function of human organic anion-transporting polypeptide OATP-B. Drug Metab Dispos 2006; 34: 577-582
• 83 Satoh H, Yamashita F, Tsujimoto M, Murakami H, Koyabu N, Ohtani H, Sawada Y. Citrus juices inhibit the function of human organic anion-transporting polypeptide OATP-B. Drug Metab Dispos 2005; 33: 518-523
• 84 Wang X, Wolkoff AW, Morris ME. Flavonoids as a novel class of human organic anion-transporting polypeptide OATP1B1 (OATP-C) modulators. Drug Metab Dispos 2005; 33: 1666-1672
• 85 Bailey DG, Dresser GK, Leake BF, Kim RB. Naringin is a major and selective clinical inhibitor of organic anion-transporting polypeptide 1A2 (OATP1A2) in grapefruit juice. Clin Pharmacol Ther 2007; 81: 495-502
• 86 Alscher DM, Klotz U. Drug interaction of herbal tea containing St. Johnʼs wort with cyclosporine. Transpl Int 2003; 16: 543-544
• 87 Bauer S, Stormer E, Johne A, Kruger H, Budde K, Neumayer HH, Roots I, Mai I. Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St Johnʼs wort in renal transplant patients. Br J Clin Pharmacol 2003; 55: 203-211
• 88 Frye RF, Fitzgerald SM, Lagattuta TF, Hruska MW, Egorin MJ. Effect of St Johnʼs wort on imatinib mesylate pharmacokinetics. Clin Pharmacol Ther 2004; 76: 323-329
• 89 Smith P, Bullock JM, Booker BM, Haas CE, Berenson CS, Jusko WJ. The influence of St. Johnʼs wort on the pharmacokinetics and protein binding of imatinib mesylate. Pharmacotherapy 2004; 24: 1508-1514
• 90 Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J. Indinavir concentrations and St Johnʼs wort. Lancet 2000; 355: 547-548
• 91 Sugimoto K, Ohmori M, Tsuruoka S, Nishiki K, Kawaguchi A, Harada K, Arakawa M, Sakamoto K, Masada M, Miyamori I, Fujimura A. Different effects of St Johnʼs wort on the pharmacokinetics of simvastatin and pravastatin. Clin Pharmacol Ther 2001; 70: 518-524
• 92 Di YM, Li CG, Xue CC, Zhou SF. Clinical drugs that interact with St. Johnʼs wort and implication in drug development. Curr Pharm Des 2008; 14: 1723-1742
• 93 Borrelli F, Izzo AA. Herb-drug interactions with St Johnʼs wort (Hypericum perforatum): an update on clinical observations. AAPS J 2009; 11: 710-727
• 94 Zhang L, Zhang Y, Huang SM. Scientific and regulatory perspectives on metabolizing enzyme-transporter interplay and its role in drug interactions: challenges in predicting drug interactions. Mol Pharm 2009; 6: 1766-1774
• 95 Patel J, Buddha B, Dey S, Pal D, Mitra AK. In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in P-gp and CYP3A4 activity. Am J Ther 2004; 11: 262-277
• 96 Nabekura T, Kamiyama S, Kitagawa S. Effects of dietary chemopreventive phytochemicals on P-glycoprotein function. Biochem Biophys Res Commun 2005; 327: 866-870
• 97 Piscitelli SC, Burstein AH, Welden N, Gallicano KD, Falloon J. The effect of garlic supplements on the pharmacokinetics of saquinavir. Clin Infect Dis 2002; 34: 234-238
• 98 Hajda J, Rentsch KM, Gubler C, Steinert H, Stieger B, Fattinger K. Garlic extract induces intestinal P-glycoprotein, but exhibits no effect on intestinal and hepatic CYP3A4 in humans. Eur J Pharm Sci 2010; 41: 729-735
• 99 Gallicano K, Foster B, Choudhri S. Effect of short-term administration of garlic supplements on single-dose ritonavir pharmacokinetics in healthy volunteers. Br J Clin Pharmacol 2003; 55: 199-202
• 100 Berginc K, Trontelj J, Kristl A. The influence of aged garlic extract on the uptake of saquinavir and darunavir into HepG2 cells and rat liver slices. Drug Metab Pharmacokinet 2010; 25: 307-313
• 101 Berginc K, Milisav I, Kristl A. Garlic flavonoids and organosulfur compounds: impact on the hepatic pharmacokinetics of saquinavir and darunavir. Drug Metab Pharmacokinet 2010; 25: 521-530
• 102 Dalvi RR. Alterations in hepatic phase I and phase II biotransformation enzymes by garlic oil in rats. Toxicol Lett 1992; 60: 299-305
• 103 Wu CC, Sheen LY, Chen HW, Kuo WW, Tsai SJ, Lii CK. Differential effects of garlic oil and its three major organosulfur components on the hepatic detoxification system in rats. J Agric Food Chem 2002; 50: 378-383
• 104 Chang TK. Activation of pregnane X receptor (PXR) and constitutive androstane receptor (CAR) by herbal medicines. AAPS J 2009; 11: 590-601
• 105 Ho BE, Shen DD, McCune JS, Bui T, Risler L, Yang Z, Ho RJ. Effects of garlic on cytochromes P450 2C9- and 3A4-mediated drug metabolism in human hepatocytes. Sci Pharm 2010; 78: 473-481
• 106 Lawson LD, Wang ZJ, Hughes BG. Identification and HPLC quantitation of the sulfides and dialk(en)yl thiosulfinates in commercial garlic products. Planta Med 1991; 57: 363-370
• 107 Lawson LD, Gardner CD. Composition, stability, and bioavailability of garlic products used in a clinical trial. J Agric Food Chem 2005; 53: 6254-6261
• 108 Saw JT, Bahari MB, Ang HH, Lim YH. Potential drug-herb interaction with antiplatelet/anticoagulant drugs. Complement Ther Clin Pract 2006; 12: 236-241
• 109 Chung KF, Dent G, McCusker M, Guinot P, Page CP, Barnes PJ. Effect of a ginkgolide mixture (BN 52063) in antagonising skin and platelet responses to platelet activating factor in man. Lancet 1987; 1: 248-251
• 110 [No authors listed] Haemorrhage due to Ginkgo biloba?. Prescrire Int 2008; 17: 19
• 111 Bone KM. Potential interaction of Ginkgo biloba leaf with antiplatelet or anticoagulant drugs: what is the evidence?. Mol Nutr Food Res 2008; 52: 764-771
• 112 Engelsen J, Nielsen JD, Winther K. Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in stable, long-term warfarin treated outpatients. A randomised, double blind, placebo-crossover trial. Thromb Haemost 2002; 87: 1075-1076
• 113 Gardner CD, Zehnder JL, Rigby AJ, Nicholus JR, Farquhar JW. Effect of Ginkgo biloba (EGb 761) and aspirin on platelet aggregation and platelet function analysis among older adults at risk of cardiovascular disease: a randomized clinical trial. Blood Coagul Fibrinolysis 2007; 18: 787-793
• 114 Aruna D, Naidu MU. Pharmacodynamic interaction studies of Ginkgo biloba with cilostazol and clopidogrel in healthy human subjects. Br J Clin Pharmacol 2007; 63: 333-338
• 115 Biber A. Pharmacokinetics of Ginkgo biloba extracts. Pharmacopsychiatry 2003; 36 (Suppl. 01) S32-S37
• 116 Koch E. Inhibition of platelet activating factor (PAF)-induced aggregation of human thrombocytes by ginkgolides: considerations on possible bleeding complications after oral intake of Ginkgo biloba extracts. Phytomedicine 2005; 12: 10-16
• 117 [no authors listed] Summaries for patients: ginseng reduces the effect of warfarin in a study of healthy volunteers. Ann Intern Med 2004; 141: 158
• 118 Lee SH, Ahn YM, Ahn SY, Doo HK, Lee BC. Interaction between warfarin and Panax ginseng in ischemic stroke patients. J Altern Complement Med 2008; 14: 715-721
• 119 Lee YH, Lee BK, Choi YJ, Yoon IK, Chang BC, Gwak HS. Interaction between warfarin and Korean red ginseng in patients with cardiac valve replacement. Int J Cardiol 2010; 145: 275-276
• 120 Yuan CS, Wei G, Dey L, Karrison T, Nahlik L, Maleckar S, Kasza K, Ang-Lee M, Moss J. Brief communication: American ginseng reduces warfarinʼs effect in healthy patients: a randomized, controlled trial. Ann Intern Med 2004; 141: 23-27
• 121 Qi LW, Wang CZ, Yuan CS. Ginsenosides from American ginseng: chemical and pharmacological diversity. Phytochemistry 2011; 72: 689-699
• 122 Legnani C, Frascaro M, Guazzaloca G, Ludovici S, Cesarano G, Coccheri S. Effects of a dried garlic preparation on fibrinolysis and platelet aggregation in healthy subjects. Arzneimittelforschung 1993; 43: 119-122
• 123 Sunter W. Warfarin and garlic. Pharm J 1991; 246: 722
• 124 Page RL, Lawrence JD. Potentiation of warfarin by dong quai. Pharmacotherapy 1999; 19: 870-876
• 125 Lau WC, Welch TD, Shields T, Rubenfire M, Tantry US, Gurbel PA. The effect of St Johnʼs Wort on the pharmacodynamic response of clopidogrel in hyporesponsive volunteers and patients: increased platelet inhibition by enhancement of CYP3A4 metabolic activity. J Cardiovasc Pharmacol 2011; 57: 86-93
• 126 Spigset O. Reduced effect of warfarin caused by ubidecarenone. Lancet 1994; 344: 1372-1373
• 127 Bristol-Myers Squibb Company. COUMADIN (warfarin sodium) tablets. Drug Label. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/009218s107lbl.pdf Accessed April 20, 2012
• 128 Shelton RC. St Johnʼs wort (Hypericum perforatum) in major depression. J Clin Psychiatry 2009; 70 (Suppl. 05) 23-27
• 129 Barbenel DM, Yusufi B, OʼShea D, Bench CJ. Mania in a patient receiving testosterone replacement postorchidectomy taking St Johnʼs wort and sertraline. J Psychopharmacol 2000; 14: 84-86
• 130 Bonetto N, Santelli L, Battistin L, Cagnin A. Serotonin syndrome and rhabdomyolysis induced by concomitant use of triptans, fluoxetine and hypericum. Cephalalgia 2007; 27: 1421-1423
• 131 Gordon JB. SSRIs and St. Johnʼs Wort: possible toxicity?. Am Fam Physician 1998; 57: 950-953
• 132 Lantz MS, Buchalter E, Giambanco V. St. Johnʼs wort and antidepressant drug interactions in the elderly. J Geriatr Psychiatry Neurol 1999; 12: 7-10
• 133 Dannawi M. Possible serotonin syndrome after combination of buspirone and St Johnʼs Wort. J Psychopharmacol 2002; 16: 401
• 134 Nathan PJ. Hypericum perforatum (St Johnʼs Wort): a non-selective reuptake inhibitor? A review of the recent advances in its pharmacology. J Psychopharmacol 2001; 15: 47-54
• 135 Schelosky L, Raffauf C, Jendroska K, Poewe W. Kava and dopamine antagonism. J Neurol Neurosurg Psychiatry 1995; 58: 639-640
• 136 Sarris J, LaPorte E, Schweitzer I. Kava: a comprehensive review of efficacy, safety, and psychopharmacology. Aust NZ J Psychiatry 2011; 45: 27-35
• 137 Zou L, Henderson GL, Harkey MR, Sakai Y, Li A. Effects of kava (Kava-kava, ʼAwa, Yaqona, Piper methysticum) on c-DNA-expressed cytochrome P450 enzymes and human cryopreserved hepatocytes. Phytomedicine 2004; 11: 285-294
• 138 Unger M, Holzgrabe U, Jacobsen W, Cummins C, Benet LZ. Inhibition of cytochrome P450 3A4 by extracts and kavalactones of Piper methysticum (Kava-Kava). Planta Med 2002; 68: 1055-1058
• 139 Almeida JC, Grimsley EW. Coma from the health food store: interaction between kava and alprazolam. Ann Intern Med 1996; 125: 940-941
• 140 Teschke R, Schulze J. Risk of kava hepatotoxicity and the FDA consumer advisory. JAMA 2010; 304: 2174-2175
• 141 Teschke R, Qiu SX, Xuan TD, Lebot V. Kava and kava hepatotoxicity: Requirements for novel experimental, ethnobotanical and clinical studies based on a review of the evidence. Phytother Res 2011; 25: 1263-1274
• 142 Jones BD, Runikis AM. Interaction of ginseng with phenelzine. J Clin Psychopharmacol 1987; 7: 201-202
• 143 Galluzzi S, Zanetti O, Binetti G, Trabucchi M, Frisoni GB. Coma in a patient with Alzheimerʼs disease taking low dose trazodone and Gingko biloba . J Neurol Neurosurg Psychiatry 2000; 68: 679-680
• 144 Gharagozloo M, Moayedi B, Zakerinia M, Hamidi M, Karimi M, Maracy M, Amirghofran Z. Combined therapy of silymarin and desferrioxamine in patients with beta-thalassemia major: a randomized double-blind clinical trial. Fundam Clin Pharmacol 2009; 23: 359-365
• 145 Aslam M, Stockley IH. Interaction between curry ingredient (karela) and drug (chlorpropamide). Lancet 1979; 1: 607
• 146 Heacock PM, Hertzler SR, Williams JA, Wolf BW. Effects of a medical food containing an herbal alpha-glucosidase inhibitor on postprandial glycemia and insulinemia in healthy adults. J Am Diet Assoc 2005; 105: 65-71
• 147 Panlasigui LN, Panlilio LM, Madrid JC. Glycaemic response in normal subjects to five different legumes commonly used in the Philippines. Int J Food Sci Nutr 1995; 46: 155-160
• 148 Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000; 38: 41-57
• 149 US Food and Drug Administration. Guidance for industry: Drug interaction studies-study design, data analysis and implications for dosing and labeling. Available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdf Accessed April 1, 2012
• 150 Zhao P, Rowland M, Huang SM. Best practice in the use of physiologically-based pharmacokinetic modeling and simulation to address clinical pharmacology regulatory questions. Clin Pharmacol Ther 2012; 92: 17-20
• 151 Fenneteau F, Poulin P, Nekka F. Physiologically based predictions of the impact of inhibition of intestinal and hepatic metabolism on human pharmacokinetics of CYP3A substrates. J Pharm Sci 2010; 99: 486-514
• 152 Na DH, Ji HY, Park EJ, Kim MS, Liu KH, Lee HS. Evaluation of metabolism-mediated herb-drug interactions. Arch Pharm Res 2011; 34: 1829-1842
• 153 Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Carrier J, Khan IA, Edwards DJ, Shah A. In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto. Clin Pharmacol Ther 2004; 76: 428-440
• 154 Markowitz JS, Devane CL, Chavin KD, Taylor RM, Ruan Y, Donovan JL. Effects of garlic (Allium sativum L.) supplementation on cytochrome P450 2D6 and 3A4 activity in healthy volunteers. Clin Pharmacol Ther 2003; 74: 170-177
• 155 Liu Z, Li Y, Li X, Ruan CC, Wang LJ, Sun GZ. The effects of dynamic changes of malonyl ginsenosides on evaluation and quality control of Panax ginseng C.A. Meyer. J Pharm Biomed Anal 2012; 64-65: 56-63
• 156 Muth M, Domanico J, Anderson D, Siegel P, Bloch L. Dietary supplement sales information final report. RTI project number 6673.004. Available at http://vm.cfsan.fda.gov/~acrobat/ds-sales.pdf Accessed February 10, 2012
• 157 US Food and Drug Administration. Current Good Manufacturing Practice in manufacturing, packaging, labeling, or holding operations for dietary supplements. Available at http://gpo.gov/fdsys/pkg/FR-2007-06-25/html/07-3039.htm Accessed June 10, 2012
• 158 US Food and Drug Administration. Federal Register Interim Final Rule − 72 FR 34959: Petition to request an exemption from 100 percent identity testing of dietary ingredients: Current good manufacturing practice in manufacturing, packaging, labeling, or holding operations for dietary supplements. Available at http://www.fda.gov/Food/DietarySupplements/GuidanceComplianceRegulatoryInformation/RegulationsLaws/ucm079573.htm Accessed June 10, 2012
• 159 Godtel-Armbrust U, Metzger A, Kroll U, Kelber O, Wojnowski L. Variability in PXR-mediated induction of CYP3A4 by commercial preparations and dry extracts of St. Johnʼs wort. Naunyn Schmiedebergs Arch Pharmacol 2007; 375: 377-382
• 160 Mai I, Bauer S, Perloff ES, Johne A, Uehleke B, Frank B, Budde K, Roots I. Hyperforin content determines the magnitude of the St Johnʼs wort-cyclosporine drug interaction. Clin Pharmacol Ther 2004; 76: 330-340
• 161 Mueller SC, Majcher-Peszynska J, Uehleke B, Klammt S, Mundkowski RG, Miekisch W, Sievers H, Bauer S, Frank B, Kundt G, Drewelow B. The extent of induction of CYP3A by St. Johnʼs wort varies among products and is linked to hyperforin dose. Eur J Clin Pharmacol 2006; 62: 29-36
• 162 Mueller SC, Majcher-Peszynska J, Mundkowski RG, Uehleke B, Klammt S, Sievers H, Lehnfeld R, Frank B, Thurow K, Kundt G, Drewelow B. No clinically relevant CYP3A induction after St. Johnʼs wort with low hyperforin content in healthy volunteers. Eur J Clin Pharmacol 2009; 65: 81-87
• 163 Vlachojannis J, Cameron M, Chrubasik S. Drug interactions with St. Johnʼs wort products. Pharmacol Res 2011; 63: 254-256
• 164 Huang SM, Hall SD, Watkins P, Love LA, Serabjit-Singh C, Betz JM, Hoffman FA, Honig P, Coates PM, Bull J, Chen ST, Kearns GL, Murray MD. Drug interactions with herbal products and grapefruit juice: a conference report. Clin Pharmacol Ther 2004; 75: 1-12
• 165 Venkataramanan R, Ramachandran V, Komoroski BJ, Zhang S, Schiff PL, Strom SC. Milk thistle, a herbal supplement, decreases the activity of CYP3A4 and uridine diphosphoglucuronosyl transferase in human hepatocyte cultures. Drug Metab Dispos 2000; 28: 1270-1273
• 166 Zuber R, Modriansky M, Dvorak Z, Rohovsky P, Ulrichova J, Simanek V, Anzenbacher P. Effect of silybin and its congeners on human liver microsomal cytochrome P450 activities. Phytother Res 2002; 16: 632-638
• 167 Brantley SJ, Oberlies NH, Kroll DJ, Paine MF. Two flavonolignans from milk thistle (Silybum marianum) inhibit CYP2C9-mediated warfarin metabolism at clinically achievable concentrations. J Pharmacol Exp Ther 2010; 332: 1081-1087
• 168 Fuhr U, Beckmann-Knopp S, Jetter A, Luck H, Mengs U. The effect of silymarin on oral nifedipine pharmacokinetics. Planta Med 2007; 73: 1429-1435
• 169 Han Y, Guo D, Chen Y, Chen Y, Tan ZR, Zhou HH. Effect of silymarin on the pharmacokinetics of losartan and its active metabolite E-3174 in healthy Chinese volunteers. Eur J Clin Pharmacol 2009; 65: 585-591
• 170 Zhang S, Morris ME. Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport. J Pharmacol Exp Ther 2003; 304: 1258-1267
• 171 Zhang S, Yang X, Morris ME. Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport. Mol Pharmacol 2004; 65: 1208-1216
• 172 Deng JW, Shon JH, Shin HJ, Park SJ, Yeo CW, Zhou HH, Song IS, Shin JG. Effect of silymarin supplement on the pharmacokinetics of rosuvastatin. Pharm Res 2008; 25: 1807-1814
• 173 Gurley BJ, Barone GW, Williams DK, Carrier J, Breen P, Yates CR, Song PF, Hubbard MA, Tong Y, Cheboyina S. Effect of milk thistle (Silybum marianum) and black cohosh (Cimicifuga racemosa) supplementation on digoxin pharmacokinetics in humans. Drug Metab Dispos 2006; 34: 69-74
• 174 DiCenzo R, Shelton M, Jordan K, Koval C, Forrest A, Reichman R, Morse G. Coadministration of milk thistle and indinavir in healthy subjects. Pharmacotherapy 2003; 23: 866-870
• 175 Piscitelli SC, Formentini E, Burstein AH, Alfaro R, Jagannatha S, Falloon J. Effect of milk thistle on the pharmacokinetics of indinavir in healthy volunteers. Pharmacotherapy 2002; 22: 551-556
• 176 Mills E, Wilson K, Clarke M, Foster B, Walker S, Rachlis B, DeGroot N, Montori VM, Gold W, Phillips E, Myers S, Gallicano K. Milk thistle and indinavir: a randomized controlled pharmacokinetics study and meta-analysis. Eur J Clin Pharmacol 2005; 61: 1-7
• 177 Rao BN, Srinivas M, Kumar YS, Rao YM. Effect of silymarin on the oral bioavailability of ranitidine in healthy human volunteers. Drug Metabol Drug Interact 2007; 22: 175-185
• 178 Rajnarayana K, Reddy MS, Vidyasagar J, Krishna DR. Study on the influence of silymarin pretreatment on metabolism and disposition of metronidazole. Arzneimittelforschung 2004; 54: 109-113
• 179 Abenavoli L, Capasso R, Milic N, Capasso F. Milk thistle in liver diseases: past, present, future. Phytother Res 2010; 24: 1423-1432
• 180 Kroll DJ, Shaw HS, Oberlies NH. Milk thistle nomenclature: why it matters in cancer research and pharmacokinetic studies. Integr Cancer Ther 2007; 6: 110-119
• 181 Schrieber SJ, Wen Z, Vourvahis M, Smith PC, Fried MW, Kashuba AD, Hawke RL. The pharmacokinetics of silymarin is altered in patients with hepatitis C virus and nonalcoholic fatty liver disease and correlates with plasma caspase-3/7 activity. Drug Metab Dispos 2008; 36: 1909-1916
• 182 Gorski JC, Huang SM, Pinto A, Hamman MA, Hilligoss JK, Zaheer NA, Desai M, Miller M, Hall SD. The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo . Clin Pharmacol Ther 2004; 75: 89-100
• 183 Xie HG, Kim RB. St Johnʼs wort-associated drug interactions: short-term inhibition and long-term induction?. Clin Pharmacol Ther 2005; 78: 19-24
• 184 Markowitz JS, Devane CL, Boulton DW, Carson SW, Nahas Z, Risch SC. Effect of St. Johnʼs wort (Hypericum perforatum) on cytochrome P-450 2D6 and 3A4 activity in healthy volunteers. Life Sci 2000; 66: L133-L139
• 185 Imai H, Kotegawa T, Tsutsumi K, Morimoto T, Eshima N, Nakano S, Ohashi K. The recovery time-course of CYP3A after induction by St Johnʼs wort administration. Br J Clin Pharmacol 2008; 65: 701-707
• 186 Dresser GK, Schwarz UI, Wilkinson GR, Kim RB. Coordinate induction of both cytochrome P4503A and MDR1 by St Johnʼs wort in healthy subjects. Clin Pharmacol Ther 2003; 73: 41-50
• 187 Hu M, Wang DQ, Xiao YJ, Mak VW, Tomlinson B. Herb-drug interactions: methods to identify potential influence of genetic variations in genes encoding drug metabolizing enzymes and drug transporters. Curr Pharm Biotechnol 2012; 13: 1718-1730
• 188 Yin OQ, Tomlinson B, Waye MM, Chow AH, Chow MS. Pharmacogenetics and herb-drug interactions: experience with Ginkgo biloba and omeprazole. Pharmacogenetics 2004; 14: 841-850
• 189 Dietary Supplement Health and Education Act of 1994 (DSHEA). Available at http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/ucm148003.htm Accessed January 29, 2012
• 190 Dietary Supplement and Nonprescription Drug Consumer Protection Act. Available at http://www.gpo.gov/fdsys/pkg/PLAW-109publ462/pdf/PLAW-109publ462.pdf Accessed June 10, 2012
• 191 US Food and Drug Administration. Requirements on the content and format of labeling for human prescription drug and biological products. Available at http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/LawsActsandRules/ucm084159.htm Accessed June 12, 2012
• 192 US Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry-Botanical drug products. Available at http://www.fda.gov/dowloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070491.pdf Accessed February 10, 2012
• 193 Wu KM, Dou J, Ghantous H, Chen S, Bigger A, Birnkrant D. Current regulatory perspectives on genotoxicity testing for botanical drug product development in the U.S.A. Regul Toxicol Pharmacol 2010; 56: 1-3
• 194 De Castro WV, Mertens-Talcott S, Rubner A, Butterweck V, Derendorf H. Variation of flavonoids and furanocoumarins in grapefruit juices: a potential source of variability in grapefruit juice-drug interaction studies. J Agric Food Chem 2006; 54: 249-255
• 195 Woelkart K, Feizlmayr E, Dittrich P, Beubler E, Pinl F, Suter A, Bauer R. Pharmacokinetics of bilobalide, ginkgolide A and B after administration of three different Ginkgo biloba L. preparations in humans. Phytother Res 2010; 24: 445-450
• 196 Ding S, Dudley E, Plummer S, Tang J, Newton RP, Brenton AG. Quantitative determination of major active components in Ginkgo biloba dietary supplements by liquid chromatography/mass spectrometry. Rapid Commun Mass Spectrom 2006; 20: 2753-2760
• 197 Kim KA, Park PW, Park JY. Short-term effect of quercetin on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein, in healthy volunteers. Eur J Clin Pharmacol 2009; 65: 609-614
• 198 Han Y, Guo D, Chen Y, Tan ZR, Zhou HH. Effect of continuous silymarin administration on oral talinolol pharmacokinetics in healthy volunteers. Xenobiotica 2009; 39: 694-699
• 199 Penzak SR, Robertson SM, Hunt JD, Chairez C, Malati CY, Alfaro RM, Stevenson JM, Kovacs JA. Echinacea purpurea significantly induces cytochrome P450 3A activity but does not alter lopinavir-ritonavir exposure in healthy subjects. Pharmacotherapy 2010; 30: 797-805
• 200 Lilja JJ, Kivisto KT, Neuvonen PJ. Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. Clin Pharmacol Ther 1998; 64: 477-483
• 201 Merck & Co.. ZOCOR (simvastatin) Tablets. Drug label. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019766s085lbl.pdf Accessed April 1, 2012
• 202 Tapaninen T, Neuvonen PJ, Niemi M. Grapefruit juice greatly reduces the plasma concentrations of the OATP2B1 and CYP3A4 substrate aliskiren. Clin Pharmacol Ther 2010; 88: 339-342